Zevra Therapeutics Beats Q3 Estimates and Sets New MIPLYFFA Sales Record
ZVRA Zevra Therapeutics Inc
$12.14 +4.75%
View chart & analysis → - 1Zevra Therapeutics exceeded headline estimates in its third-quarter results.
- 2Zevra Therapeutics achieved an adjusted EPS of $0.18 for the third quarter, representing a 28.6% surprise.
- 3U.S. MIPLYFFA net sales reached a record $34 million, up 12.6% from the previous quarter.
So what's the key point?
Zevra Therapeutics earned more profit than experts expected. Drug sales also grew to $34 million, reaching a record level.
Source Earnings Whispers · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.